Intravenous vitamin C refers to the method of administering vitamin C parenterally i. By comparison, oral administration of vitamin C is dependant on absorption through the gut and must be processed by the liver before it enters the bloodstream and other tissues in the body. There are limits as to how much vitamin C can be absorbed through the gut and consequently alter plasma blood levels of vitamin C to have an effect. Intravenous vitamin C is used clinically to achieve plasma levels of vitamin C far exceeding what can be achieved by oral supplementation.
Studies of combined oral and i. Median overall survival for the combination arm was Four observational studies were reported using both i. All patients had incurable malignancies. Details of concurrent treatment were limited. Both studies reported improved survival in the ascorbate-treated arm most common ascorbate treatment protocol was 10 g i.
A further retrospective observational study by Cameron and Campbell [ 46 ] in patients with a variety of stages and types of malignancy reported improved survival in patients who had received ascorbate at any stage during their malignancy in three district general hospitals compared with those who had not received ascorbate during their malignancy.
The authors reported average survival times of days versus 35 days for high- versus low-dose and no ascorbate in one hospital cohort and versus 48 days in his second cohort of high- versus low-dose and no ascorbate [ 47 ]; no confidence intervals for survival times or statistical analysis was presented in this paper.
Two studies administering both oral and i. One dose-finding study by Hoffer et al. Patients were treated with up to 1. Ascorbate was reported to be well-tolerated with the maximum toxicities being grade 2 there was no reference as to what toxicity grading scale was used. No tumor response was seen.
The four other studies using oral and i. Patients were treated both with ascorbate alone and in combination with chemotherapy.
A variety of outcomes were reported. Previous Section Next Section Discussion The absolute extent of ascorbate use in patients with malignancy is unknown but widespread.
One survey of complementary medicine practitioners revealed that of these practitioners delivered ascorbate to 11, patients in and 8, patients in The average dose given was 28 g every 4 days for 22 doses per person [ 18 ].
The same publication surveyed manufacturers of ascorbate in the U. With the varying requirements for registration and licensure of practitioners of complementary medicine and the classification of oral ascorbate as a food by the Food and Drug Administration, data on the number of patients receiving ascorbate is difficult to accurately obtain.
The anecdotal experience of the authors would suggest it is commonly used by patients while also receiving treatment for cancer at an academic cancer center.
This systematic review was performed to identify evidence related to the use of ascorbate in cancer patients and its impact on clinically relevant and validated outcomes. Many studies were small. Heterogeneity across included studies was considerable in terms of study design, patient characteristics, ascorbate treatment regimens, concurrent treatments administered, and outcomes measured.Implications for Practice: Many cancer patients receive ascorbate (vitamin C) in conjunction with chemotherapy.
There is no high-quality evidence to suggest that ascorbate either enhances the antitumor effects of chemotherapy or reduces its toxicity.
Vitamin C is one of the most commonly consumed supplements, however, the safety and benefits of oral vitamin C supplement use among cancer survivors has not been established,, and few studies have specifically examined vitamin C supplement use among women with breast cancer.
Tumor-bearing mice fed high doses of vitamin C (antioxidant) along with adriamycin (pro-oxidant) had a prolonged life and no reduction in the tumor-killing capacity of adriamycin. 6 Lung cancer patients who were provided antioxidant nutrients prior to, during, and after radiation and chemotherapy had enhanced tumor destruction and a.
determine the safety and tolerability of g/kg intravenous vitamin C (IVC) over minutes given times per week to cancer patients during the course of chemotherapy including documentation of side effects and toxicity;.
Along with its needed effects, ascorbic acid (the active ingredient contained in Vitamin C) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
I received high dose IV vitamin C throughout my treatment with carbo/taxol/avastin. It kept my strong enough to receive two additional chemo rounds, which I think contributed to my good outcome.
It also reduced the side effects from the chemo drugs. University of Kansas research indicates it is Reviews: